Universitat Internacional de Catalunya

uic.es

Total trials

147

Active

35

Phase 3

1

Total enrollment

11,553

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 2 of 2 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Penicillin1
Carbamide peroxide 10%1

Next readouts

  • 2024-12-31
  • 2026-05

Top conditions

  • Peri-Implantitis12
  • Peri-implant Mucositis8
  • Dental Implant5
  • Gingival Recession4
  • Stroke4
  • Peri-implantitis3
  • Neuromuscular Diseases3
  • Stroke Sequelae3

Frequently asked questions about Universitat Internacional de Catalunya

How many clinical trials does Universitat Internacional de Catalunya have on ClinicalTrials.gov?
Universitat Internacional de Catalunya is listed as the lead sponsor on 147 clinical trials in ClinicalTrials.gov, 35 of which are currently active (recruiting, enrolling, or ongoing).
How many of Universitat Internacional de Catalunya's trials are in Phase 3?
1 of Universitat Internacional de Catalunya's trials are in Phase 3, spread across 2 active drug programs.
What therapeutic areas does Universitat Internacional de Catalunya focus on?
Universitat Internacional de Catalunya's most-studied conditions on ClinicalTrials.gov are Peri-Implantitis, Peri-implant Mucositis, Dental Implant, Gingival Recession, Stroke.
When are Universitat Internacional de Catalunya's next clinical trial readouts?
Universitat Internacional de Catalunya has 2 upcoming primary-completion readouts tracked here; the soonest is “Do Penicillin-allergic Patients Presents a High Risk of Sinus Lift Failure”, expected around 2024-12-31.